Enanta Pharmaceuticals (ENTA) Jefferies 2024 Global Healthcare Conference summary

Strategic focus and pipeline evolution

• Expanding beyond virology into immunology to build shareholder value, with a new focus on chronic spontaneous urticaria (CSU) and a KIT inhibitor program announced earlier this year.

• Planning to announce a second immunology program later this year, aiming to use immunology as a platform for further growth.

• Legacy in virology includes successful hepatitis C drugs and ongoing work in hepatitis B, RSV, and human metapneumovirus.

RSV clinical development and trial design

• Two RSV molecules advancing: zelicapavir (N protein inhibitor) in high-risk peds and adults, and EDP-323 (L protein inhibitor) in a human challenge study.

• Human challenge study data for EDP-323 expected next quarter; pediatric high-risk study data expected in the second half of the year.

• RSVPEDs study focuses on dose selection and safety in pediatrics, with efficacy trends to inform phase III design.

• Inclusion criteria for RSV studies: five-day symptom onset cut for peds, three-day for adults, reflecting differences in disease progression.

• Both inpatient and outpatient pediatric populations included to capture a range of disease severity and inform future trial design.

KIT inhibitor program and safety considerations

• Oral small molecule KIT inhibitor program prioritizes safety, robust efficacy, and once-daily dosing; candidate selection excludes molecules with reactive metabolites to avoid liver toxicity.

• Confident in preclinical safety measures and in vivo tox screening to select a finalist with optimal characteristics.

• Neutropenia is considered mechanism-based but tends to be reversible and manageable; small molecules offer tunability advantages over antibodies.

• Targeting both Xolair-naive and Xolair-refractory CSU populations, with potential to expand to other mast cell-driven diseases such as CIndU, EoE, PN, asthma, and atopic dermatitis.